This Week: and lots more… On its Q4 2022 Earnings Call, COMPASS Pathways executives shared an important update to the company’s Phase 3 program, which is made up of two Phase 3 trials of COMP360 psilocybin therapy for treatment-resistant depression (TRD). (For a refresher, see our overview of the company’s Phase 3 program, as originally announced, in Bulletin 120.) Most notably…


Previous articleWebinar – Unraveling the Top 3 Psychedelic Neuroscience Myths
Next articleatai Life Sciences Announces Key Clinical Pipeline and Corporate Updates